Document:

Exhibit
10.1

 

TERMINATION
AGREEMENT

 

THIS
TERMINATION AGREEMENT (the “Agreement”) is made, entered into and effective as of January 1, 2016 (“Effective
Date”), by and among Blaise J. Wolfrum, M.D. (the “Seller”), Behavioral Health Care Associates, Ltd., an Illinois
corporation (the “Company”), and Accelera Innovations, Inc., a Delaware corporation (the “Purchaser”).
All parties to this Agreement may be individually referred to herein as a “Party” or collectively as the “Parties.”

 

RECITALS

 

WHEREAS,
the Seller, Company, and Purchaser are Parties to the following agreements: Stock Purchase Agreement dated on or about
November 20, 2013, First Amendment to the Stock Purchase Agreement dated February 24, 2014, Second Amendment to the Stock Purchase
Agreement dated March 18, 2014, Third Amendment to the Stock Purchase Agreement dated May 30, 2014, Fourth Amendment to the Stock
Purchase Agreement dated May 31, 2015, Employment Agreement and Employee Confidentiality, Non-Circumvention and Non-Solicitation
Agreement dated on or about November 20, 2013, Stock Pledge and Escrow Agreement dated on or about November 20, 2013, Stock Power
Certificate dated on or about November 20, 2013, Bill of Sale dated on or about November 20, 2013, Assignment of Stock dated on
or about November 20, 2013, and other written and oral agreements or understandings relating to the aforementioned agreements
(hereinafter collectively referred to as the “Stock Sale Agreements”);

 

WHEREAS,
the Purchaser did not make the payments to Seller as required by the Stock Sale Agreements, as amended; and,

 

WHEREAS,
the Parties now desire to terminate the Stock Sale Agreements as of the Effective Date.

 

NOW,
THEREFORE, in consideration of mutual promises contained herein, and in consideration of the above recitals, which are incorporated
into this Agreement by reference, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
it is agreed as follow:

 

1.
 Termination. Upon the execution of this Agreement by all Parties, the Stock Sale Agreements (other than this Agreement)
shall be terminated, null and void, and of no further force or effect, and any and all rights, duties and obligations arising
thereunder or in connection with Stock Sale Agreements (other than this Agreement) are now and hereafter fully and finally terminated,
except for the Surviving Obligations (defined below), which shall survive such termination and shall continue in full force and
effect. For the avoidance of doubt, it is the intention of the Parties that no provision of the Stock Sale Agreements shall survive
the termination of such Stock Sale Agreements pursuant to this Agreement, notwithstanding any indication to the contrary in either
such agreement, except for this Agreement and the Surviving Obligations.

 

    	- 1 -

    	 

    

 

2. Surviving
Obligations. The Parties agree that only the following obligations shall survive the termination of such Stock Sale Agreements
(the “Surviving Obligations”):

 

A.
The Parties agree and reaffirm their previous agreement that Purchaser has conveyed and transferred or shall convey or transfer
Seventy Thousand (70,000) Shares of Stock in Purchaser. The Seller shall be fully vested in the Seventy Thousand (70,000) Shares
of Stock upon the execution of this Agreement by all Parties. The Seventy Thousand (70,000) Shares of Stock shall be unrestricted
and free trading stock and free and clear of all liens, security interests, pledges,
restrictions, encumbrances, equities, claims, charges, voting agreements, voting trusts, proxies
and rights of any kind, nature or description, except for restrictions imposed under federal securities laws.

 

B.
Purchaser, at its sole cost and expense, shall immediately take any and all actions required to remove all restrictions on the
Seventy Thousand (70,000) Shares of Stock in Purchaser, including, without limitation, the provision of an attorney opinion letter
satisfactory to Purchaser to the extent legally permissible under federal securities laws.

 

C.
The Parties agree that Purchaser has transferred or conveyed or shall transfer and convey Six Hundred Thousand (600,000) Shares
of Stock in Purchaser. The Seller shall be fully vested the Six Hundred Thousand (600,000)
Shares of Stock upon the execution of this Agreement by all Parties. The Six Hundred Thousand (600,000) Shares of Stock shall
be free and clear of all liens, security interests, pledges, restrictions, encumbrances,
equities, claims, charges, voting agreements, voting trusts, proxies and rights of any
kind, nature or description, except for the terms and conditions of the Lock-Up and Leak-Out Agreement dated November 20, 2013
and restrictions imposed under federal securities laws.

 

D.
Purchaser, at its sole cost and expense, shall take any and all actions required to remove all restrictions on the Six Hundred
Thousand (600,000) Shares of Stock, including, without limitation, the provision of an attorney opinion letter satisfactory to
Purchaser to the extent legally permissible under federal securities laws, subject to the terms and conditions of the Lock-Up
and Leak-Out Agreement dated November 20, 2013.

 

E.
The transfer of
Shares from Purchaser to
Seller is irrevocable
and non-refundable under any circumstance.
The Parties agree that the transfer of Shares
from Purchaser to Seller shall not be
deemed to be consideration under or pursuant to any of the Stock Sale Agreements.

 

3.
 Audit. Upon execution of this Agreement, Seller shall permit Purchaser, at Purchaser’s sole cost and expense, to
conduct a commercially reasonable audit of the Company consistent with the nature and scope of previous audits performed by Purchaser
of the Company.

 

4. Form
8-K. Within four (4) business days of the execution of this Agreement, Purchaser shall file with the U.S. Securities and Exchange
Commission a Form 8-K disclosing the terms and termination of the Stock Sale Agreements.

 

    	- 2 -

    	 

    

 

5. Internal
Revenue Service. The Purchaser warrants and represents that it has not filed and shall not file or cause or authorize to be
filed any tax return with the Internal Revenue Service or state revenue agency that recognizes the revenues or expenses of the
Company or otherwise claims an ownership interest in the Company after the Effective Date.

 

6.
 Purchaser’s Release of Seller and Company. Purchaser, and any affiliate of Purchaser or other parties claiming by
or through Purchaser, agrees to generally and forever release and discharge Seller and Company, and any and all of Company’s
affiliated entities, parents, subsidiaries, successors, assigns, shareholders, directors, officers, employees, agents, attorneys,
and other representatives, from any and all claims, actions, lawsuits, obligations, or liability, monetary or otherwise, whether
known or unknown, arising from or related to the Stock Sale Agreements, or any other issue or matter arising prior to or on the
date of full execution of this Agreement. In addition, Purchaser, and any affiliate of Purchaser or other parties claiming by
or through Purchaser, agrees and covenants not to make, commence, file, or assert against Seller and Company, and any and all
of Company’s affiliated entities, parents, subsidiaries, successors, assigns, shareholders, directors, officers, employees,
agents, attorneys, and other representatives, any claim, lawsuit, action, or other request for relief arising from or related
to the Stock Sale Agreements, or any other issue or matter arising prior to or on the date of full execution of this Agreement.

 

7.
 Purchaser’s Indemnification of Seller and Company. Purchaser and Purchaser’s affiliates shall defend, indemnify,
and hold harmless Seller and Company, and any and all of Company’s affiliated entities, parents, subsidiaries, successors,
assigns, shareholders, directors, officers, employees, agents, attorneys, and other representatives (each for the purpose of this
Agreement, an “Seller Indemnitee”) from and against any and all claims, damages, losses, and expenses, including reasonable
attorneys’ fees, suffered or incurred, including any incidental, consequential, special, exemplary or punitive damages by
any such Seller Indemnitee arising from, relating to or otherwise in respect of (i) the Stock Sale Agreements, (ii) any breach
of any covenant, warranty, or agreement in this Agreement, (iii) oral or written statements made by Purchaser to third parties,
including auditors and the U.S. Securities and Exchange Commission, concerning or relating to the Stock Sale Agreements, and (iv)
documents provided to third parties by Purchaser, including auditors and the U.S. Securities and Exchange Commission, concerning
or relating to the Stock Sale Agreements.

 

8. Remedies.
All Parties shall have the right to recover damages resulting from any breach of this Agreement, which shall be cumulative
and non-exclusive. Should Purchaser or an affiliate of Purchaser commence any lawsuit or other action against Seller or Company,
or any and all of Company’s affiliated entities, parents, subsidiaries, successors, assigns, shareholders, directors, officers,
employees, agents, attorneys, and other representatives, for any claim arising from or related to this Agreement or the Stock
Sale Agreements, Seller and Company shall be entitled, in addition to such other relief as may be granted, to an award of all
of its reasonable costs and expenses, including, but not limited to, expert fees, and reasonable attorneys’ fees incurred
in connection therewith from Purchaser and Purchaser’s affiliates.

 

    	- 3 -

    	 

    

 

9. Governing
Law: This Agreement shall be governed by and interpreted under Illinois law, including its choice of law provisions. Any and
all disputes arising from or relating to this Agreement shall be brought in the Circuit Court of DuPage County, Illinois.

 

10. Severability.
Notwithstanding any other provision in this Agreement, if any part or provision of this Agreement is declared or held unenforceable,
such declaration shall not affect any other part or provision of this Agreement.

 

11. Recitals.
The Recitals to this Agreement are to be read as part of this Agreement and are specifically incorporated herein.

 

12. Authorized
Signatures and Counterparts. The Parties to this Agreement represent and warrant that the persons who execute this Agreement
have actual or apparent authority to bind the Party to the terms and conditions of this Agreement. The Parties also agree that
this Agreement may be executed in counterparts, and all counterparted executions shall be treated as a single execution of this
Agreement by all Parties. The Parties also agree that faxed, scanned, or other photocopied signatures on this Agreement shall
be treated as original signatures.

 

13. Further
Assurances. The Parties shall execute such further documents and do any and all such
further things as may be necessary subject to applicable federal securities laws to implement and carry out the intent of this
Agreement, including, without limitation, the removal of the restrictions on the 670,000 Shares of Stock
in Purchaser. Purchaser further agrees to timely take all action(s) necessary to clear the 670,000 Shares of Stock in Purchaser
of restriction, including, without limitation, (i) authorizing the Purchaser’s transfer agent to remove the restrictive
legend, (ii) expediting the acquisition of a legal opinion from the Purchaser’s authorized counsel at the Purchaser’s
expense, (iii) delivering any additional documentation that may be required by the Seller, its broker or the transfer agent in
connection with the legend removal request, including Rule 144 share representation letters and a resolution of the Board of Directors
evidencing proper issuance of the 670,000 Shares of Stock, and (iv) cooperating and communicating with the Seller, its broker
and the transfer agent in order to clear the 670,000 Shares of Stock of restriction as soon as reasonably possible.

 

14. Construction.
The Parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question
of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption
or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this
Agreement.

 

15. Amendments
and Waivers. No amendment of any provision of this Agreement shall be valid unless the same shall be in writing and signed
by each of the Parties. No waiver by any Party of any provision of this Agreement of any default, misrepresentation, or breach
of warranty or covenant hereunder, whether intentional or not, shall be valid unless the same shall be in writing and signed by
the Party making such waiver nor shall such waiver be deemed to extend to any prior or subsequent default, misrepresentation,
or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such
occurrence.

 

    	- 4 -

    	 

    

 

16. Headings.
The section headings contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning
or interpretation of this Agreement.

 

17. No
Third Party Beneficiaries. This Agreement shall not confer any rights or remedies upon any person or entity other than the
Parties and their respective successors and permitted assigns.

 

18. Entire
Agreement. This Agreement constitutes the entire agreement among the Parties and supersedes any prior understandings, agreements,
or representations by or among the Parties, written or oral, to the extent they relate in any way to the subject matter hereof.

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Termination Agreement effective as of the date set forth below.

 

[THIS
SPACE INTENTIONALLY LEFT
BLANK; SIGNATURE PAGE
FOLLOWS]

 

    	- 5 -

    	 

    

 

[TERMINATION
AGREEMENT SIGNATURE PAGE]

 

	Dated
    as of March 31, 2016.	 
	 	 
	 	Blaise
    J. Wolfrum, M.D. 
	 	(“SELLER”)
	 	 
	 	/s/
    Blaise J. Wolfrum, M.D.
	 	By:	 Blaise
    J. Wolfrum, M.D.
	 	 
	 	Accelera
                    Innovations, Inc. 

        (“PURCHASER”)

	 	 
	 	/s/
    Cindy Boerum
	 	By:	Cindy Boerum
	 	Its:	President
	 	 
	 	Behavioral
                    Health Care Associates 

        (“COMPANY”)

	 	 
	 	/s/
    Blaise J. Wolfrum, M.D.
	 	By:	Blaise J. Wolfrum,
    M.D.
	 	Its:	President

 

[THIS
SPACE INTENTIONALLY LEFT
BLANK]

 

    	- 6 -Exhibit
10.2 

 

RESIGNATION
AND RELEASE AGREEMENT

 

THIS
RESIGNATION AND RELEASE AGREEMENT (the “Agreement”) is made, entered into and effective as of January 1, 2016
(“Effective Date”), by and among Blaise J. Wolfrum, M.D., Accelera Healthcare Management Service Organization, LLC
(the “Company”), and Accelera Innovations, Inc., (“Accelera”). All parties to this Agreement may be individually
referred to herein as a “Party” or collectively as the “Parties.”

 

1.
 Resignation. Blaise J. Wolfrum, M.D. hereby resigns as the Manager and from any and all positions of the Company, effective
immediately.

 

2.
 Release. The Company and Accelera, and any of their affiliates or other parties claiming by or through the Company or
Accelera, agree to generally and forever release and discharge Blaise J. Wolfrum, M.D., from any and all claims, actions, lawsuits,
obligations, or liability, monetary or otherwise, whether known or unknown, arising from or related to the Operating Agreement
of the Company, his performance and actions as Manager of the Company, or any other issue or matter arising prior to or on the
date of full execution of this Agreement. In addition, the Company and Accelera, and any of their affiliates or other parties
claiming by or through the Company or Accelera, agree and covenant not to make, commence, file, or assert against Blaise J. Wolfrum,
M.D., any claim, lawsuit, action, or other request for relief arising from or related to the Operating Agreement of the Company,
his performance and actions as Manager of the Company, or any other issue or matter arising prior to or on the date of full execution
of this Agreement.

 

3. Indemnification
of Seller and Company. The Company and Accelera, and their respective affiliates, shall defend, indemnify, and hold harmless
Blaise J. Wolfrum, M.D. from and against any and all claims, damages, losses, and expenses, including reasonable attorneys’
fees, suffered or incurred, including any incidental, consequential, special, exemplary or punitive damages by Blaise J. Wolfrum,
M.D arising from, relating to or otherwise in respect of (i) the Operating Agreement of the Company, (ii) the operation of the
business of the Company, and, (iii) any breach of any covenant, warranty, or agreement in this Agreement.

 

4. Remedies.
All Parties shall have the right to recover damages resulting from any breach of this Agreement, which shall be cumulative
and non-exclusive. Should Company or Accelera or an affiliate of Company or Accelera commence any lawsuit or other action against
Blaise J. Wolfrum, M.D., for any claim arising from or related to this Agreement, Blaise J. Wolfrum, M.D. shall be entitled, in
addition to such other relief as may be granted, to an award of all of its reasonable costs and expenses, including, but not limited
to, expert fees, and reasonable attorneys’ fees incurred in connection therewith from Company or Accelera and their respective
affiliates.

 

    	 

    	 

    

 

5. Governing
Law: This Agreement shall be governed by and interpreted under Illinois law, including its choice of law provisions. Any and
all disputes arising from or relating to this Agreement shall be brought in the Circuit Court of DuPage County, Illinois.

 

6. Severability.
Notwithstanding any other provision in this Agreement, if any part or provision of this Agreement is declared or held unenforceable,
such declaration shall not affect any other part or provision of this Agreement.

 

7. Authorized
Signatures and Counterparts. The Parties to this Agreement represent and warrant that the persons who execute this Agreement
have actual or apparent authority to bind the Party to the terms and conditions of this Agreement. The Parties also agree that
this Agreement may be executed in counterparts, and all counterparted executions shall be treated as a single execution of this
Agreement by all Parties. The Parties also agree that faxed, scanned, or other photocopied signatures on this Agreement shall
be treated as original signatures.

 

8. Construction.
The Parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question
of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption
or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this
Agreement.

 

9. Amendments
and Waivers. No amendment of any provision of this Agreement shall be valid unless the same shall be in writing and signed
by each of the Parties. No waiver by any Party of any provision of this Agreement of any default, misrepresentation, or breach
of warranty or covenant hereunder, whether intentional or not, shall be valid unless the same shall be in writing and signed by
the Party making such waiver nor shall such waiver be deemed to extend to any prior or subsequent default, misrepresentation,
or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such
occurrence.

 

10. Headings.
The section headings contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning
or interpretation of this Agreement.

 

11. No
Third Party Beneficiaries. This Agreement shall not confer any rights or remedies upon any person or entity other than the
Parties and their respective successors and permitted assigns.

 

12. Entire
Agreement. This Agreement constitutes the entire agreement among the Parties and supersedes any prior understandings, agreements,
or representations by or among the Parties, written or oral, to the extent they relate in any way to the subject matter hereof.

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Resignation and Release Agreement effective as of the Effective Date.

 

[THIS
SPACE INTENTIONALLY LEFT
BLANK; SIGNATURE PAGE
FOLLOWS]

 

    	 

    	 

    

 

[TERMINATION
AGREEMENT SIGNATURE PAGE]

 

	 	Blaise
    J. Wolfrum, M.D.
	 	 
	 	/s/
    Blaise J. Wolfrum, M.D
	 	By:
    	Blaise
    J. Wolfrum, M.D.
	 	 
	 	Accelera
    Innovations, Inc.
	 	 
	 	/s/
    Cindy Boerum
	 	By:	Cindy
    Boerum 
	 	Its:	President
	 	 
	 	Accelera
    Healthcare Management Service Organization, LLC
	 	 
	 	/s/
    Cindy Boerum
	 	Accelera
    Innovations, Inc.
	 	By:	Cindy
    Boerum
	 	Its:	President

 

[THIS
SPACE INTENTIONALLY LEFT
BLANK]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}]]